15 Background: Residual HIV-1 replication among individuals under antiretroviral therapy 16 (ART) relates to HIV micro-inflammation. 17 Objectives: To determine levels of residual HIV replication markers among distinct 18 subgroups of antiretroviral-treated individuals.
Introduction 40
The deleterious effects of HIV are directly related to viral replication, which leads to 41 inflammatory processes, such as the activation of CD4+ and CD8+ T lymphocytes (1). 42 Maintaining viral replication at lower levels is critical for the reduction of cellular activation 43 and co-morbidities related to HIV-1 infection. However, the antiretroviral therapy (ART) 44 currently used does not completely suppress viral replication. Up to 80% of patients with 45 undetectable viral loads according to commercial tests show an average of 3.1 copies/mL of 46 residual viral load when ultrasensitive tests are used (2, 3) . Although the stability of episomal 47 DNA is not completely understood, extrachromosomal DNA is useful as a surrogate marker 48 of HIV-1 replication when the HIV viral load is not detectable by currently available methods 49 (4). Other markers that relate to HIV-1 replication among individuals under ART include 50 proviral HIV DNA (5) and the quantitation of HIV antibody levels (6) or markers that relate 51 to bacterial translocation (7) . ART regimens differ in potency as well as in the distinct genetic 52 barriers they create or effects they have in each step of the HIV replication cycle to alter viral 53 dynamics. For this reason, the evaluation of circular HIV DNA could be used as a tool to 54 indirectly compare the effectiveness of these distinct regimens on residual HIV replication. 55 Therefore, this study aimed to analyze surrogate markers of the residual replication rates of 56 HIV-1 among individuals receiving different antiretroviral regimens. We hypothesize that 57 drugs from different classes and previous ART virologic failure will affect surrogate markers 58 of HIV residual replication.
59

Methods
60
Episomal DNA 114 The general patient data including age, gender, CD4+ and CD8+ T-lymphocyte 115 counts, treatment time, number of regimens and number of medications used were compiled 116 and are shown in Tables 1 and 2, grouped according to the type of ART received. 117 2-LTR circles were detected in 39 (34%) of the patients in the study. Table 3 118 summarizes the measurements obtained according to treatment group. The treatment group 119 had no effect on the quantitation of episomal HIV DNA (F (115,4) = 1.263, p = 0.289). The 120 prevalence of detectable 2-LTR (n=39) was not different between the groups (F(38,4)=1.014, 121 p=0.414).
122
There was no difference in the quantitation of 2-LTR circles among groups with first 123 treatment (F(49,1) = 1.429, p = 0.23, Figure 1A ). Additionally, there was no difference (F 124 (47,1) = 1.692, p = 0.20) when comparing the 2 distinct salvage therapy groups. We also 125 observed no difference between the two groups receiving PI-r (F(50,1)=0.197, p=0.65).
126
Furthermore, there was no significant difference between the first treatment groups together 127 and the salvage groups together, (F (98,1) = 1.229, p = 0.27) nor when comparing the groups 128 with virologic success to that of virologic failure (F (114,1) = 0.601, p = 0.44). 7 samples in the failure group (χ 2 (3) = 4.259, p = 0.039, Figure 2A ). In addition, the mean of 137 total DNA was higher among individuals with positive episomal DNA (ANOVA, F (109,1) = 138 2.794, p = 0.09; Figure 2B ).
139
Total HIV DNA 140 Total HIV DNA was detected in 111 (96%) of the patients included in the study 141 (Table 3 ). An ANOVA tests showed no differences between the treatment groups for 142 quantitation of total HIV DNA (F (115,4) = 2.015, p = 0.098; Table 3 and Figure 1B ).
143
Additionally, there was no difference in total HIV DNA quantitation between the groups with 144 a first-line regimen (Groups 1 and 2, F(47,1) = 0.010, p = 0.922), nor between the two groups 145 on salvage therapy (Groups 3 and 4, F (44,1) = 1.230, p = 0.273), nor between the groups on 146 a first-line regimen and salvage therapy (F (93,1) = 0.007, p = 0.935). Finally, there was a 147 difference between the groups with virologic success and virologic failure (F (109,1) = 7.528, 148 p = 0.007) in which virological failure group shows higher total HIV DNA mean.
149
There was no statistical significance between total HIV DNA and the other tested 150 variables.
151
Quantitation of anti-HIV-1 antibodies 152
In this test, we considered samples with normalized optical densities (ODn) higher or 153 equal to 0.8 as positive. Table 3 summarizes the measurements obtained according to 154 treatment group. ANOVA showed no differences in the HIV antibody levels between the 155 groups (F (115,4) = 1.675, p = 0.161, Figure 1C ). However, the antibody levels were higher 156 among patients given first treatment with NNRTI compared to first treatment with PI-r 157 (ANOVA; F (49,1) = 5.189, p = 0.027). There was no difference when comparing the two 158 types of salvage therapy schemes (F(47,1)=0.189, p = 0.66) nor between the first-line 159 treatment and salvage therapy groups (F(98,1)=0.146, p = 0.70). In addition, there was no 160 8 difference when comparing the groups with virologic successful and virologic failure 161 (F(114,1)=1.289, p = 0.25).
162
Considering ODn as a categorical variable in which positive samples had an ODn ≥ 163 0.8, there was a decreased number of positive samples in the first treatment group using PI-r 164 (χ 2 (1) = 9.600, p = 0.007) compared to the first treatment group using NNRTI as well as an 165 increase in positivity when compared to salvage therapy with PI (χ 2 (1) = 4.038, p = 0.044) 166 ( Figure 3 ). There was no significant difference between the first-line regimen groups and the 167 salvage therapy groups, (χ 2 (1)=0.360, p=0.34) nor any difference when comparing groups 168 with or without virologic failure (χ 2 (1)=1.945, p=0.13).
169
Positive antibody quantitation was not associated with the positivity of episomal 170 DNA (χ 2 (1) = 1.889, p = 0.119) or with the episomal DNA quantitation (F(114,1)=0.112, 171 P=0.738). Patients with positive antibody quantitation showed slightly higher HIV total DNA 172 (F(109,1)=2.787, p=0.09).
173
LPS quantitation 174
Due to the unavailability of samples, LPS quantitation was performed for only 55 175 patients (Table 3 ). An ANOVA test showed a significant difference between the first-line 176 regimen groups, with LPS higher among individuals treated with NNRTI compared to PI-r 177 (F(55,4)=2.947, p= 0.029, Figure 1D ), as well as between the NNRTI and salvage therapy 178 groups and the PI-r group (p=0.019, Bonferroni Test).
179
Correlations 180
Spearman correlation tests were performed only with samples in which episomal 181 DNA was detected. There was a negative correlation between the quantitation of episomal 182 DNA and the CD8+ T-cell count (ρ = -0.426, p = 0.007) and the CD4+ T-cell count (ρ = -183 9 0.276, p = 0.08), LPS quantitation in plasma (ρ = -0.500, p = 0.041) and treatment time with 184 an undetectable viral load (ρ = -0.358, p = 0.044).
185
Spearman correlation between total HIV DNA showed positive correlation with 186 episomal DNA quantitation (ρ = 0.256, p = 0.007), antibody levels (ρ = 0.181, p = 0.05) and 187 also a negative correlation with CD8+ T-cell count (ρ = -0.243, p = 0.01) and trend to 188 correlate with CD4+ T-cell count (ρ = -0.16, p = 0.09). antibodies detected using less sensitive assays also relate to the levels of HIV-1 replication 212 (6). As HIV-1 residual replication may come from the gastrointestinal tract (12), it is also 213 conceivable that less effective antiretroviral treatment could be associated with higher levels 214 of bacterial translocation (7) and therefore increasing laboratory translocation markers such 215 as LPS or sCD14 levels. 216 We also wanted to investigate the relationship between different HIV ART schemes 217 or strategies. The main questions were: is initial treatment more suppressive when two (17). The other question is whether salvage therapy is associated with 224 more residual HIV replication than initial antiretroviral therapy. Usually, salvage therapy 225 relies on a boosted PI-based regimen with or without the use of a new antiretroviral class.
226
Therefore, a further question would be whether the association of a third antiretroviral class 227 would more suppressive than salvage therapy schemes containing 2 NRTIs and a boosted PI 228 only. We therefore performed a cross-sectional evaluation of a distinct group of individuals 229 under "suppressive" antiretroviral treatment with good treatment adherence using 2 NRTIs 230 and either efavirenz/nevirapine or PI-r as the first-line treatment. We also evaluated 231 individuals who previously experienced antiretroviral virologic failure and had their HIV 232 viremia subsequently suppressed with 2 NRTIs and a PI-r only or PI-r associated to 233 raltegravir. We also used as a "control group", individuals experiencing virologic failure in 234 which antiretroviral resistance had been detected. We attempted to avoid individuals not 235 using or adhering to ART at the time of the study. 236 We were able to confirm the relationship between HIV-1 replication and the detection 237 of episomal DNA, which was higher among individuals experiencing virologic failure 238 compared to individuals with viral loads below detection, even with the smaller sample size 239 of the virologic failure group. 240 We also detected a negative correlation between episomal DNA quantitation and the 241 time of treatment with undetectable viral loads as well as a negative correlation between 242 episomal DNA and CD8+ T-cell counts. It is conceivable that lower CD8 levels enable HIV-243 1 viral replication, as has been seen in animal models; the elimination of CD8+ T cells using 244 monoclonal antibodies was associated with the return of detectable viremia in SIV-infected 245 monkeys in spite of the use of suppressive ART (18). Likewise, we hypothesize that longer 246 durations of effective antiretroviral treatment will progressively strengthen the immune 247 system, by increasing the number of naïve CD4+ T cells and thus further decreasing residual 248 HIV-1 replication. This speculation is further supported by the observation of a negative 249 correlation between the levels of episomal DNA and CD4+ T-cell counts. However, we were 250 not able to explain the negative correlation between episomal DNA levels and LPS levels.
251
Interestingly, the levels of total HIV DNA were found to be higher among individuals 252 with evidence of residual HIV replication as inferred by the presence of episomal DNA. This 253 association suggests that the pool of infected cells is being replenished or maintained in 254 association with residual HIV replication. 255 We were not able to detect any differences between episomal or total DNA levels 256 between first-line regimens and successful salvage therapy regimens, nor between NNRTI 257 versus PI-r regimens or salvage therapy using two or three classes (NRTI + PI-r versus NRTI 258 12 + PI-r and raltegravir). However, the levels of antibodies were lower in first-line PI-r ART 259 compared to the NNRTI group as the number of negative antibody results were higher among 260 the initial PI-r treatment group. Furthermore, the levels of LPS were higher among the 261 NNRTI first-line treatment group compared to the first-line PI-r or other salvage therapy 262 groups that also have a PI-r in the treatment scheme. Notably, the proportion of patients 263 taking tenofovir, abacavir or zidovudine was similar in the PI-r and NNRTI groups ( Table   264   S1 ). Although clinical trials have noted that NNRTI-based regimens are usually more durable 265 and effective than PI-r-based regimens despite a basal viral load and higher CD4+ T-cell 266 levels, these results are mainly due to better performance of intention to treat analyses, which 267 are influenced by tolerance and adherence issues. Importantly, 14 individuals in the PI-r 268 group were treated with boosted atazanavir, whereas 11 were treated with boosted lopinavir 269 [Table S1 ]. However, this study analyzed patients on stable ART without adherence or 270 tolerability issues. We can therefore hypothesize that the effective inhibition of two different 271 steps of the HIV replicative cycle is more effective than inhibiting only one step. 272 We recognize that the retrospective cross-sectional nature of this study may preclude 273 more definite conclusions. The evaluation of only one time point in this group prevents us 274 from understanding the dynamics of these surrogate markers for HIV replication.
275
Furthermore, other sensitive assays measuring residual HIV replication, such as cell-276 associated RNA or inflammatory markers, have not been evaluated here.
277
However, we were able to clearly demonstrate that episomal DNA was present in 26% 278 to 38% of individuals with "successful" antiretroviral treatment, thus suggesting that residual 279 HIV replication is occurring despite the scheme analyzed here. We were also able to 280 demonstrate the association of PI-r schemes with lower antibody and LPS levels, which 281 deserves further confirmation to better understand the related mechanisms involved that can 282 explain these findings. The authors have no competing interests to declare. 
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